CTLA4 and metastatic neoplasm: Currently, the use of monoclonal antibodies targeting cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4), PD-1, and Program Cell Death Ligand 1 (PD-L1) has remained limited to unresectable, locally advanced and metastatic disease.